Land: USA
Språk: engelska
Källa: NLM (National Library of Medicine)
Butalbital (UNII: KHS0AZ4JVK) (Butalbital - UNII:KHS0AZ4JVK), Acetaminophen (UNII: 362O9ITL9D) (Acetaminophen - UNII:362O9ITL9D), Caffeine (UNII: 3G6A5W338E) (Caffeine - UNII:3G6A5W338E)
Alvogen Inc.
Butalbital
Butalbital 50 mg
ORAL
PRESCRIPTION DRUG
Butalbital, Acetaminophen, and Caffeine Tablets USP is indicated for the relief of the symptom complex of tension (or muscle contraction) headache. Evidence supporting the efficacy and safety of this Butalbital, Acetaminophen, and Caffeine Tablets USP in the treatment of multiple recurrent headaches is unavailable. Caution in this regard is required because butalbital is habit-forming and potentially abusable. Butalbital, Acetaminophen, and Caffeine Tablets USP is contraindicated under the following conditions: - Hypersensitivity or intolerance to any component of Butalbital, Acetaminophen, and Caffeine Tablets USP - Patients with porphyria. Abuse and Dependence Butalbital Barbiturates may be habit-forming: Tolerance, psychological dependence, and physical dependence may occur especially following prolonged use of high doses of barbiturates. The average daily dose for the barbiturate addict is usually about 1500 mg. As tolerance to barbiturates develops, the amount needed to maintain the same level of
Butalbital, Acetaminophen, and Caffeine Tablets USP Containing 50 mg butalbital, 325 mg acetaminophen, and 40 mg caffeine. Available as blue, round uncoated tablets, engraved “t 247” on one side and plain on other side. Bottles of 100 (NDC 47781-536-01) and 500 (NDC 47781-536-05). Store at 20º to 25°C (68° to 77°F); excursions permitted within 15º to 30º C (59º to 86º F). [see USP Controlled Room Temperature]
Abbreviated New Drug Application
BUTALBITAL, ACETAMINOPHEN, AND CAFFEINE - BUTALBITAL, ACETAMINOPHEN, AND CAFFEINE TABLET ALVOGEN INC. ---------- BUTALBITAL, ACETAMINOPHEN, AND CAFFEINE TABLETS USP RX ONLY HEPATOTOXICITY ACETAMINOPHEN HAS BEEN ASSOCIATED WITH CASES OF ACUTE LIVER FAILURE, AT TIMES RESULTING IN LIVER TRANSPLANT AND DEATH. MOST OF THE CASES OF LIVER INJURY ARE ASSOCIATED WITH THE USE OF ACETAMINOPHEN AT DOSES THAT EXCEED 4000 MILLIGRAMS PER DAY, AND OFTEN INVOLVE MORE THAN ONE ACETAMINOPHEN CONTAINING PRODUCT. DESCRIPTION Butalbital, Acetaminophen, and Caffeine Tablets USP is supplied in tablet form for oral administration. Each tablet contains the following active ingredients: butalbital, USP.........................50 mg acetaminophen, USP..............325 mg caffeine, USP...........................40 mg _Inactive Ingredients:_ crospovidone, croscarmellose sodium, FD&C Blue #1, magnesium stearate, microcrystalline cellulose, povidone, pregelatinized starch and stearic acid. Butalbital (5-allyl-5-isobutylbarbituric acid), is a short to intermediate-acting barbiturate. It has the following structural formula: C H N O Mol. wt. 224.26 Acetaminophen (4′-hydroxyacetanilide), is a non-opiate, non-salicylate analgesic and antipyretic. It has the following structural formula: C H NO Mol. wt. 151.17 Caffeine (1,3,7-trimethylxanthine), is a central nervous system stimulant. It has the following structural formula: 11 16 2 3 8 9 2 C H N O Mol. wt. 194.19 CLINICAL PHARMACOLOGY Butalbital, Acetaminophen, and Caffeine Tablets USP is intended as a treatment for tension headache. It consists of a fixed combination of butalbital, acetaminophen, and caffeine. The role each component plays in the relief of the complex of symptoms known as tension headache is incompletely understood. PHARMACOKINETICS The behavior of the individual components is described below. _BUTALBITAL_ Butalbital is well absorbed from the gastrointestinal tract and is expected to distribute to most tissues in the body. Barbiturates in general may appear in breast milk and rea Läs hela dokumentet